This website is best viewed using the vertical display on your mobile device.

This website is best viewed using the horizontal display on your tablet device.

INDICATIONS

Considering ELIQUIS

ELIQUIS IS
FDA-APPROVED

In clinical trials for patients
with DVT/PE, ELIQUIS:

Treated DVT/PE blood clots and had less major bleeding in a 6-month study vs. LOVENOX® (enoxaparin) followed by warfarin.

Helped prevent another DVT/PE in a separate 12-month study vs. placebo.

ELIQUIS and other blood thinners
increase the risk of bleeding, which can
be serious, and rarely may lead to death.

In the 6-month study vs. LOVENOX® followed by warfarin:
Almost 98% of patients on ELIQUIS didn’t experience another DVT/PE blood clot.

If you're taking warfarin, consider talking to your doctor about ELIQUIS for both these reasons: ELIQUIS was proven effective to
treat deep vein thrombosis (DVT) and
pulmonary embolism (PE) blood clots. Plus,
ELIQUIS had significantly less major bleeding*
than the standard of care, LOVENOX®
followed by warfarin.

*Major bleeding included noticeable bleeding with at least
1 of the following—a transfusion of 2 or more units of
blood; bleeding that occurred in the brain, spine, eye, inside
the abdomen, around the heart, in a joint, or in a muscle,
leading to damage; or fatal bleeding.

Questions about DVT/PE and
blood thinners?
Learn more about DVT/PE.

ELIQUIS WAS STUDIED

IN THE FOLLOWING 2 CLINICAL TRIALS

Clinical trial results are important because they can help doctors consider and choose the right treatment for you based on their efficacy and safety results.

+ Expand All

Clinical Trial 1

ELIQUIS was proven to treat dvt/pe

In a clinical trial, ELIQUIS was tested against LOVENOX® (enoxaparin) followed by warfarin (LOVENOX®/warfarin), a standard treatment, for the first 6 months after DVT/PE.

This trial included more than 5,200 patients who had DVT/PE—about half were on LOVENOX®/warfarin and the other half were on ELIQUIS.

Clinical Trial EFFICACY Results

In the trial, ELIQUIS and LOVENOX®/warfarin had similar efficacy results.

2.7%

2.7% or 71 out of 2,635
patients on LOVENOX®/warfarin
had DVT/PE

2.3%

2.3% OR 59 out of 2,609
patients on ELIQUIS had DVT/PE

In this trial, bleeding events were also compared.

Clinical trial safety results

In the trial, those who were on ELIQUIS had significantly less major bleeding compared to those who were on LOVENOX®/warfarin.

On LOVENOX®/warfarin

1.8%

49 out of 2,689 patients
had major bleeding

On ELIQUIS

0.6%

15 out of 2,676 patients
had major bleeding

ELIQUIS and other blood thinners increase the risk of bleeding, which can be serious, and rarely may lead to death.

Absolute reduction was 1.2% (1.8% – 0.6% = 1.2%). Relative risk reduction was 69%, which means that patients on ELIQUIS had 69% less chance of major bleeding than patients on LOVENOX®/warfarin.

HOW WAS MAJOR BLEEDING DEFINED?

Major bleeding included noticeable bleeding with at least 1 of the following—
a transfusion of 2 or more units of blood; bleeding that occurred in the brain, spine, eye, inside the abdomen, around the heart, in a joint, or in a muscle, leading to damage; or fatal bleeding.

Trial outcomE

In this trial, ELIQUIS had similar efficacy
and significantly less major bleeding
than LOVENOX®/warfarin.

Based on these results, ELIQUIS was approved to treat DVT/PE blood clots.

Clinical Trial 2

ELiquis significantly reduced the risk of another dvt/pe after initial treatment†

This trial evaluated ELIQUIS versus placebo in more than 1,600 patients for reducing the risk of a DVT/PE happening again. It looked at the effects of treating patients with ELIQUIS for an additional 12 months after they had completed their initial 6-12 month
treatment for DVT/PE with a blood thinner. In this trial, there were a similar number of
patients on ELIQUIS compared to placebo.
829 patients were taking placebo; 840 were
taking 2.5 mg ELIQUIS twice a day.

†Versus placebo.

Clinical trial efficacy results

Those who took ELIQUIS to reduce the risk of recurrence had less chance of having another DVT/PE clot compared to placebo.

On placebo

11.6%

96 out of 829 patients
had a recurrence

On ELIQUIS

3.8%

32 out of 840 patients
had a recurrence

Absolute reduction was 7.8% (11.6% – 3.8% = 7.8%). Relative risk reduction was 67%, which means that patients on ELIQUIS had 67% less chance of DVT/PE recurrence than patients on placebo.

What is a placebo?

A placebo is a pill that contains no medicine. It’s sometimes called a sugar pill. In “double-blind” clinical trials—like this one for ELIQUIS—neither the patients nor the doctors conducting the trials know who is given placebo and who is given the actual medicine—the pills look the same.

Clinical trial safety results

Major bleeding was also studied

This trial studied major bleeding in patients on ELIQUIS and in patients on placebo.

On placebo

0.5%

4 out of 826 patients
had major bleeding

On ELIQUIS

0.2%

2 out of 840 patients
had major bleeding

ELIQUIS and other blood thinners increase the risk of bleeding, which can be serious, and rarely may lead to death.

How was major bleeding defined?

Major bleeding included noticeable bleeding with at least 1 of the following—a transfusion of 2 or more units of blood; bleeding that occurred in the brain, spine, eye, inside the abdomen, around the heart, in a joint, or in a muscle, leading to damage; or fatal bleeding.

Trial outcomE

In this study, ELIQUIS significantly reduced
the risk of having another DVT/PE after
initial treatment versus placebo. Based on these results, ELIQUIS was approved to reduce the risk of DVT/PE blood clots occurring again.

SELECTED IMPORTANT SAFETY INFORMATION

ELIQUIS can cause bleeding, which can be serious, and rarely may lead to death. This is because ELIQUIS is a blood thinner medicine that reduces blood clotting. While taking ELIQUIS, you may bruise more easily and it may take longer than usual for any bleeding to stop.

You may have a higher risk of bleeding if you take ELIQUIS and take other medicines that increase your risk of bleeding, such as aspirin, nonsteroidal anti-inflammatory drugs (called NSAIDs), warfarin, heparin, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), and other medicines to help prevent or treat blood clots. Tell your doctor about all of the medicines you take, including any over-the-counter medicines, vitamins, and herbal supplements.

Spinal or epidural blood clots (hematoma). People who take ELIQUIS, and have medicine injected into their spinal or epidural area, or have a spinal puncture, have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis).

Please read additional Important Safety Information, including Boxed WARNINGS below.

More Reasons to Consider ELIQUIS

It's important for you and your doctor to discuss your lifestyle when choosing a
blood thinner. Here are some other things to know about taking ELIQUIS.

With ELIQUIS there are no known dietary restrictions or watch-outs for foods like leafy greens.

Patients taking ELIQUIS do not have to go for routine INR* blood testing.

*International Normalized Ratio

If you are currently prescribed warfarin, be sure to discuss INR blood testing or foods to watch out for with your doctor.

Keep in mind that warfarin and ELIQUIS are both prescription medicines. Only your doctor can decide which blood thinner is right for you.

Learn about some
possible side effects of ELIQUIS.

Back to Top

MORE TO EXPLORE

TALKING TO YOUR DOCTOR

Get tips for talking with your doctor
about ELIQUIS.

meet kathy

Kathy, a real patient, shares her story
about taking ELIQUIS.

Kathy is an actual patient. She was compensated for
her time and expenses.

coverage assistance

We’ll help you find out if ELIQUIS is covered by your prescription insurance.
−

Important facts about
ELIQUIS® (apixaban) This is a summary of important safety information that you need
to know about ELIQUIS.

Look out for the following
icons as
you read:

Talk to your healthcare team

Call a healthcare provider right away

Helpful information to remember

Do not stop taking ELIQUIS without talking to the doctor who prescribed it to you For patients taking ELIQUIS for atrial fibrillation: stopping
ELIQUIS increases your risk of having a stroke.

Talk to your healthcare team before any medical procedures. ELIQUIS may need to be stopped before surgery or a
medical or dental procedure. Your doctor will tell you when you should stop taking ELIQUIS and when you may start
taking it again.
If you have to stop taking ELIQUIS, your doctor may prescribe another medicine to help prevent a blood
clot from forming.

What are the possible serious side effects of ELIQUIS? This is a list of some of the serious side effects of ELIQUIS.

Bleeding

ELIQUIS can cause bleeding, which can be serious, and rarely may lead to death. This is because ELIQUIS is a blood thinner medicine that reduces blood clotting. While taking ELIQUIS, you may bruise more easily and it may take longer than usual for any bleeding to stop.

You may have a higher risk of bleeding if you take ELIQUIS with other medicines that increase your risk of bleeding, such as:

  • Aspirin
  • Nonsteroidal anti-inflammatory
    drugs (called NSAIDs)
  • Warfarin
  • Heparin
  • Selective serotonin reuptake
    inhibitors (SSRIs) or serotonin
    norepinephrine reuptake inhibitors (SNRIs)
  • Other medicines to help prevent or treat blood clots

Tell your doctor if you take any of these medicines.

Call your doctor or get medical help right away if you have any of these signs or symptoms of bleeding when taking ELIQUIS:

  • Unexpected bleeding or bleeding

    that lasts a long time, such as:
    • Unusual bleeding from
      the gums
    • Nosebleeds that
      happen often
    • Menstrual or vaginal
      bleeding
      that is heavier
      than normal
  • Bleeding that is severe or you cannot control
  • Red, pink, or brown urine
  • Red or black stools
    (looks like tar)
  • Coughing up or vomiting blood
  • Vomit that looks like coffee grounds
  • Unexpected pain, swelling, or joint pain
  • Headaches
  • Feeling dizzy or weak

Spinal or epidural blood clots (hematoma)

People who take ELIQUIS, and have
medicine injected into their spinal or
epidural area, or have a spinal puncture,
have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (paralysis).

Your risk of developing a spinal or epidural blood clot is higher if:

  • A thin tube called an epidural catheter
    is placed in your back
    to
    give you
    certain medicine
  • You take NSAIDs or a medicine
    to
    prevent blood from clotting
  • You have a history of difficult or repeated epidural or spinal punctures
  • You have a history of problems with
    your spine or have had surgery on
    your spine

If you take ELIQUIS and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots or bleeding.

Tell your doctor right away if you have any of these signs or symptoms (especially in your legs and feet) when taking ELIQUIS:

  • Tingling
  • Numbness
  • Muscle weakness

A reaction to ELIQUIS itself

A reaction to ELIQUIS can cause hives, rash, itching, and possibly trouble breathing. If you get this reaction, it will usually happen soon after you take a dose of ELIQUIS.

Get medical help right away if you have any of the following symptoms:

  • Sudden chest pain or
    chest tightness
  • Sudden swelling of your face
    or
    tongue
  • Trouble breathing
  • Wheezing
  • Feeling dizzy or faint

Talk to your doctor about any side effect that may be bothering you or that does not go away. These are not all of the possible side effects of ELIQUIS. Call your doctor for medical advice about side effects.

You are encouraged to report any side effects to the FDA at 1-800-FDA-1088. 1-800-FDA-1088.

Who should not take ELIQUIS?

ELIQUIS is not for patients who:

  • have artificial heart valves
  • have antiphospholipid syndrome (APS),
    especially with positive
    triple antibody testing, who have
    a history of blood clots
  • currently have certain types of abnormal bleeding
  • have had a serious allergic reaction
    to ELIQUIS

What should I discuss with my healthcare team before starting ELIQUIS?

Talk to your healthcare team about the following:

  • Kidney or liver problems
  • If you have antiphospholipid
    syndrome
  • Any other medical conditions
  • If you have ever had bleeding problems

Tell your doctor if you are pregnant or breastfeeding, or planning to become pregnant or breastfeed. You and your doctor should decide if you will take ELIQUIS or breastfeed. You should not do both.

Females who are able to become pregnant: talk with your healthcare provider about pregnancy planning, and your risk of severe uterine bleeding if you are treated with blood thinner medicines, including ELIQUIS.

Tell your healthcare team about all the medicines you take, including any:

  • prescription medicines
  • over-the-counter medicines
  • vitamins
  • herbal supplements

During treatment, make sure you talk to your healthcare team before you begin to take any new medication.

How should I take ELIQUIS?

Take ELIQUIS exactly as prescribed by your doctor.

Twice daily

With or without food

Do not change your dose or stop taking ELIQUIS unless your doctor tells you to.

What if I miss a dose of ELIQUIS?

If you miss a dose of ELIQUIS, take it as soon as you remember, and do not take more than one dose at the same time.

When should I refill my prescription?

If you are taking ELIQUIS for atrial fibrillation, stopping ELIQUIS may increase your risk of having a stroke. Do not
run out of ELIQUIS. Refill your prescription before
you run out. When leaving the hospital following hip or knee replacement, be sure that
you will have ELIQUIS available to avoid missing any doses.

ELIQUIS is available in two different tablets. Your doctor or healthcare provider will determine what dose is right for you.

2.5 mg tablet

Round, with a pale yellow color

OR

5 mg tablet

Oval, with a pale orange or pink color

Note: Images do not represent actual tablet size.

On one side of each tablet, there is a number indicating the dosage
strength of the tablet (in milligrams).
On the other side, there is a
medication identification number.

What is ELIQUIS?
ELIQUIS is a prescription medicine used to:

Reduce the risk of stroke and
blood clots in people who have
atrial fibrillation (AFib),
a type of irregular heartbeat,
not
caused by a heart valve
problem.

Treat blood clots in the
veins of the legs (deep vein thrombosis – DVT) or lungs
(pulmonary embolism – PE), and
reduce the risk of them occurring again.

Reduce the risk of forming a
blood clot in the legs (DVT)
and lungs (PE) of people who
have just had hip or knee replacement surgery.

Please see U.S. Full Prescribing Information, including Boxed WARNINGS and Medication Guide.

LOVENOX® is a registered trademark of Aventis Pharma S.A.

The product information provided in this
site is intended only for residents of the
United States. The products discussed herein may have different product labeling in
different countries.

The health information contained herein is provided for educational purposes only and is not intended to replace discussions with
a healthcare provider. All decisions
regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. 1-800-FDA-1088.

+

SELECTED IMPORTANT SAFETY INFORMATION & INDICATIONS

For people taking ELIQUIS® (apixaban) for atrial fibrillation: Do not stop taking ELIQUIS without talking to the doctor who prescribed it for you. Stopping ELIQUIS increases your risk of having a stroke.

ELIQUIS may need to be stopped prior to surgery or a medical or dental procedure. Your doctor will tell you when you should stop taking ELIQUIS and when you may start taking it again. If you have to stop taking ELIQUIS, your doctor may prescribe another medicine to help prevent a blood clot from forming.

ELIQUIS can cause bleeding, which can be serious, and rarely may lead to death. This is because ELIQUIS is a blood thinner medicine that reduces blood clotting.

You may have a higher risk of bleeding if you take ELIQUIS and take other medicines that increase your risk of bleeding, such as aspirin, nonsteroidal anti-inflammatory drugs (called NSAIDs), warfarin (COUMADIN®), heparin, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), and other medicines to help prevent or treat blood clots. Tell your doctor about all of the medicines you take, including any over-the-counter medicines, vitamins, and herbal supplements.

AFib Not Caused by
a Heart Valve Problem

DVT/PE

Hip or Knee
Replacement Surgery

ELIQUIS® and the ELIQUIS logo are trademarks
of Bristol-Myers Squibb Company.

All other trademarks are property of their
respective companies.

© 2022 Bristol-Myers Squibb Company.
432-US-2200454  10/22